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185 An investigation into microbial contamination of physiotherapy
airway clearance equipment in children with cystic ﬁbrosis
S. Rand1,2, L. Hill2, J. Soothill3, S.A. Prasad2. 1Portex Unit, UCL Institute of
Child Health, London, United Kingdom; 2Cystic Fibrosis Unit, Great Ormond
Street Hospital for Children NHS Trust, London, United Kingdom; 3Microbiology
Department, Great Ormond Street Hospital for Children NHS Trust, London,
United Kingdom
Objective: Infection prevention and control measures in CF care are designed to
decrease the risk of exposure to harmful CF pathogens. Written cleaning guidelines
are provided when a new piece of airway clearance equipment is introduced and
verbal guidelines are given to CF families at regular intervals as standard practice
in our centre. The aim of this audit was to investigate the levels of microbial
contamination of physiotherapy airway clearance equipment.
Method: Information was taken regarding the ‘normal’ routine of cleaning and
sterilisation of equipment at home from parents/children. A standardised protocol
to swab the physiotherapy airway clearance equipment was used and a cough swab
or sputum sample was obtained at the same time from each child for comparison.
Results: Swabs from 5 CF patients were analysed. The results showed variety in
the frequency and methods of cleaning and sterilising the equipment and in the
methods of drying and storing the equipment. Microbial contamination was evident
on all of the airway clearance equipment and included coliforms, Stenotrophomonas
maltophilia, Acinetobacter species and commensals. The 2 pieces of equipment
from which the Stenotrophomonas maltophilia and Acinetobacter species were
cultured were from 2 individuals who had no evidence of these microbes in their
cough swab/sputum samples.
Conclusion: This small study highlights the need for vigorous and effective
cleaning and sterilisation of all airway clearance equipment as per manufacturer’s
guidelines. Better education and increased vigilance by clinicians is essential to
ensure potential contamination by CF pathogens from airway clearance equipment
is prevented.
186 High volumes of hypertonic saline integrated with chest
physiotherapy in CF patients
S. Hammer1, V. Dreyer1, B.N. Lærum2. 1Haukeland University Hospital,
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Background: Nebulised hypertonic saline (HS) is an established basic airway
clearance treatment in CF. However, there is scarce evidence regarding the practical
implementation and administration of different HS volumes, including physiother-
apy and aspects of breathing pattern.
Aim: To establish a safe, efﬁcient routine for implementation of HS in daily
treatment and to investigate the efﬁciency and tolerance of high volumes of HS
integrated with chest physiotherapy.
Methods: Eight CF patients not using HS were invited. Seven patients (5 children,
2 adults; mean age 15.3 yrs) answered questionnaires with visual analogue scales
(VAS 1−10), measured mucus volumes and performed lung function tests one week
before, at introduction of 3.35% HS concentration, at 5.8% HS and 5, 12 weeks and
up to mean 89.3 weeks (SD 7.7) after initiation of HS. Salbutamol was inhaled prior
to HS. HS was given twice daily with volumes of 4.5ml in children aged 0−5 years,
6ml at age 6−16 years and 9ml at age >16 years. The protocol included guidance
of standardized breathing pattern, upright and sideways positioning and voluntary
cough.
Results: Seven CF patients completed the study. All patients tolerated 3.35% and
5.8% HS well. Mean volume of mucus increased from 15.3ml (SD 18.4) to
76.4ml (SD 87.53) with 5.8% HS. Satisfaction with daily treatment increased from
VAS 6.7 (SD 1.03) to 8.3 (SD 0.95). Lung function (FEV1 %pred.) increased from
89.3% (SD 9.06) to 94.9% (SD 8.43).
Conclusion: In this small, in depth study the introduction of high volumes of
5.8% HS with standardised breathing patterns and positioning twice daily was well
tolerated, improved airway clearance and slightly improved lung function.
187 The need for bronchodilators before airway clearance therapy
sessions in CF
M.C. Rodriguez Hortal1,2, L. Hjelte1,2. 1Karolinska University Hospital,
Stockholm, Sweden; 2Karolinska Institutet, Stockholm, Sweden
Objective: The aim of this study was to evaluate the effect of inhaled bronchodila-
tors on pulmonary function (FVC and FEV1) before chest physiotherapy in CF.
Methods: We consecutively included 50 patients, 21 adults (32±15 yrs) and 29
children (11±4 yrs), who met the physiotherapist for an airway clearance therapy
session. Mean lung function at inclusion was: FVC 87±0.2% and FEV1 73±0.3%
of predicted.
Each patient performed a spirometry before the session after having inhaled short-
acting b2-agonists (Salbutamol) (38 via MDPI, 8 via e-ﬂow, and 2 patients via
pMDI). One patient inhaled a selective short-acting b2-agonist via turbohaler
(Terbutalin), one inhaled long-acting b2-agonist (Formoterol). All the patients were
tested on two different occasions to identify intra-individual variation.
Results: Mean FVC before the session were: 2.45±1.12 L; after bronchodilation:
2.58±1.13 L. (p = 0.000014). Mean FEV1 before the session were: 1.86±0.8 L, after
bronchodilation: 1.96±0.8 L. (p = 0.000542). However, only 9 patients increased
their FEV1 by 10% or more. The intra-individual results were not signiﬁcant
consistent.
Conclusion: Beta-2 agonists improved lung function to some extent in most patients
but regular inhalation of bronchodilators prior to chest physiotherapy may still be
questioned. Individual assessment is needed to evaluate whether a less than 10%
effect on lung function justiﬁes the use of these agents.
188 The short term effect of airway clearance using the
“Cough Assist” on lung function in patients with cystic ﬁbrosis
G. Sokol1, R. Hakimi1, R. Better1, O. Efrati1. 1Edmond and Lili Safra Childrens
Hospital, The Pediatric Pulmonary Unit, Ramat Gan, Israel
Background: CoughAssist is a noninvasive therapy that safely removes secretions
by gradually applying a positive pressure to the airway, then rapidly shifting to
negative pressure. Our aim was to study the effect of airway clearance using the
cough assist on lung function in the short term in cystic ﬁbrosis (CF) patients.
Methods: Eighteen CF patients (age 12−35 yrs.) were studied during their routine
visits to the clinic. The “Pegaso cough” by “Dima italia” and the “Emerson
CoughAssist™” by “Philips Respironics” were randomly used to perform airway
clearance. Patients performed inhalations and exhalation using the cough assist
which was operated manually by an experienced physiotherapist which synchronized
the machines inssuﬂation and exsufﬂation cycle to the patients breathing cycle. The
insufﬂation and exsufﬂation pressures were set to +20 cmH2O and −40 cmH2O
respectively. The breathing cycles continued until mucus was transported from the
peripheral to the central airways, and was followed by spontaneous cough.
The entire procedure was repeated for 20 minutes.
Pulmonary function test (PFT) were measured before and 15 minutes after treat-
ment. A change of 10% from baseline values of FVC or FEV1, was considered
signiﬁcant.
Results: the mean improvement in FVC and FEV1 was 9.01%±9.1 and 7.98%±4.6
respectively (p< 0.001). 9 patients (50%) improved PFT above 10% baseline values.
Conclusions: Airway clearance performed by cough assist signiﬁcantly improved
short-term lung function in CF patients. The combination of mechanical inssuﬂation
and exsufﬂation, followed by spontaneous cough, might give a new tool for CF
patients to clear secretions from the lungs.
